Orca Biosystems, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.orcabio.com
Clinical Trials
4
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Reduced Intensity or Nonmyeloablative Conditioning With Orca-T for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
- Conditions
- Leukemia, Myeloid, AcuteMyelodysplastic SyndromesMixed Phenotype Acute Leukemia
- Interventions
- First Posted Date
- 2025-10-14
- Last Posted Date
- 2025-10-28
- Lead Sponsor
- Orca Biosystems, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT07216443
- Locations
- 🇺🇸
UCLA Department of Medicine, Los Angeles, California, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Lymphoid LeukemiaTherapy-Related Myelodysplastic SyndromeMixed Phenotype Acute LeukemiaUndifferentiated LeukemiaAcute Leukemia
- Interventions
- Biological: Standard-of-Care
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Orca Biosystems, Inc.
- Target Recruit Count
- 187
- Registration Number
- NCT05316701
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸UC Davis, Sacramento, California, United States
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Conditions
- Acute Myeloid LeukemiaAcute Lymphoid LeukemiaChronic Myeloid LeukemiaAcute LeukemiaBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Orca Biosystems, Inc.
- Target Recruit Count
- 255
- Registration Number
- NCT04013685
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸UC Davis, Sacramento, California, United States
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic SyndromesMixed Phenotype Acute Leukemia
- Interventions
- Biological: OrcaGraft (Orca-Q)
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Orca Biosystems, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT03802695
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸UC Davis, Sacramento, California, United States
🇺🇸Stanford Health Care, Stanford, California, United States
News
Advancements in Acute Lymphocytic Leukemia (ALL) Treatment Landscape
The FDA approved obecabtagene autoleucel (Aucatzyl) for adults with relapsed or refractory B-cell precursor ALL, marking a significant advancement in CAR T-cell therapy.